Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) / Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Project: Research

Project Details

StatusActive
Effective start/end date04/29/25 → 11/30/29

Funding

  • Akero Therapeutics Incorporated: $89,481.82